Q32 Bio (QTTB) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.44
- Estimate
- -$0.54
- Surprise
- +18.8%
- Score today
- 6.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Q32 Bio (QTTB) reported a narrower loss than forecast — adjusted EPS of -$0.44 against the -$0.54 estimate (a 18.8% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates QTTB Hold at 6.5/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +18.8% surprise compares with a +180.4% four-quarter average.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $39.60 vs price $8.37 — ratio 4.7×). Rejected, falling back to technical TP.
- Market cap $245M below $400M minimum
- Momentum score 2.2/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.37
- Price target
- $11.76
- Stop
- $7.78
- Upside to target
- +40.5%
Risk check: RSI 21 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-06 — shown for context, not personalized investment advice.
QTTB at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $245.0M
- P/E (fwd)
- -8.1
- P/E (ttm)
- 2.6
- 52-week range
- $1.91–$23.57
- Off 52-week high
- 64.5%
- RSI (14)
- 21
- Volume vs avg
- 0.81×
- Score today
- 6.5/10